Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Consensus Target Price from Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $8.50.

A number of equities analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Gossamer Bio in a research report on Thursday, September 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Gossamer Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Gossamer Bio Trading Up 0.3%

NASDAQ GOSS opened at $3.44 on Friday. Gossamer Bio has a 1 year low of $0.76 and a 1 year high of $3.87. The company has a market cap of $796.22 million, a PE ratio of -4.99 and a beta of 1.92. The stock’s 50-day moving average price is $2.86 and its two-hundred day moving average price is $2.33.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%.The firm had revenue of $13.29 million during the quarter, compared to analysts’ expectations of $6.32 million. Research analysts forecast that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Gossamer Bio

Large investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock worth $77,000 after purchasing an additional 43,866 shares during the period. Invesco Ltd. purchased a new stake in Gossamer Bio in the 1st quarter worth approximately $48,000. OMERS ADMINISTRATION Corp purchased a new stake in Gossamer Bio in the 1st quarter worth approximately $387,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Gossamer Bio during the 1st quarter valued at $213,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Gossamer Bio by 720.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after acquiring an additional 825,047 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.